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Heat shock protein 90 (Hsp90) is a highly conserved and dynamic molecular chaperone 
protein important for regulating protein activity and interactions in cellular signaling and 
adaptive stress responses. As a key regulatory protein, Hsp90 is often manipulated by cancer 
cells to enhance tumorigenic cell growth and even exists in some tumors as a multimeric 
complex called the “epichaperome.” With its linked role in cancer proliferation, Hsp90 serves as 
a promising cancer therapeutic target, with many Hsp90 inhibitors developed including 
geldanamycin and PU-H71. With limited information existing regarding epichaperome formation 
and structure, this study seeks to investigate potential regulatory mechanisms for epichaperome 
stabilization. In this study, we investigate the conformational states of Hsp90 targeted by 
geldanamycin and PU-H71 using chemical cross-linking and mass spectrometric analysis. Our 
data suggests that geldanamycin targets an open-like conformation of Hsp90, while PU-H71 
targets a closed-like conformation of Hsp90 in a multicomplex epichaperome. Additionally, we 
detected enriched phosphorylation in the charged linker region of PU-H71-bound Hsp90 at 
residues S226 and S255. Mammalian expression vectors were developed containing mCherry 
linked to Hsp90. Within the Hsp90 sequence, S226 and S255 were mutated to phosphomimetic 
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or phosphorylation-null amino acids. Confocal microscopy and immunoprecipitation analysis of 
mCherry linked to Hsp90 revealed that phosphorylation null mutants were associated much less 
with Hsp90 co-chaperones than unmutated Hsp90 and phosphomimetic mutated Hsp90. Overall, 
the results indicated that phosphorylation likely plays an important role in epichaperome 




RESEARCH GOALS, HYPOTHESIS, AND PROJECT AIMS 
 
Heat shock protein 90 (Hsp90) is a dynamic molecular chaperone protein, which facilitates 
the folding, activation, and binding of other proteins. It is an essential protein in the cell, and its 
function is often hijacked for the proliferation and survival of cancer. Consequently, Hsp90 is an 
interesting therapeutic target for treating cancer. Two Hsp90 inhibitors are geldanamycin (GA) 
and PU-H71 (PU), where GA targets Hsp90 unassociated with fellow client and co-chaperone 
proteins and PU targets Hsp90 in its “epichaperome” conformation, which consists of Hsp90 and 
numerous other client and co-chaperone proteins. As a dynamic chaperone protein, Hsp90 adopts 
multiple conformations to perform its many functions. Maintaining specific conformations can 
be aided by posttranslational modifications. The main goal of this thesis is to characterize Hsp90 
subpopulations targeted by PU and GA. Information obtained regarding Hsp90 targeted by PU 
will provide insight into what factors aid in epichaperome stabilization and assembly.  
The hypothesis of this thesis is that phosphorylation of Hsp90 regulates its conformation in 
the epichaperome and its interactions with other chaperone proteins. To test this hypothesis, 
there are two main aims: 1) characterize Hsp90 modifications targeted by GA and PU and 2) 
generate posttranslationally modified Hsp90 mutants and assess the effects of posttranslational 
modifications (PTMs) on Hsp90 co-chaperone and client proteins. 
For Aim 1, I took the following steps to characterize Hsp90 modifications. The first step is to 
identify phosphorylation sites on Hsp90. By identifying the amino acid residues phosphorylated 
and comparing their amount in GA and PU-bound Hsp90 subpopulations to global Hsp90 
modification levels in the lysate, the biochemical nature of Hsp90 populations targeted by Hsp90 
inhibitors can be characterized. Some modifications enriched or depleted in PU-bound Hsp90 
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may regulate the conformational states of Hsp90 and facilitate the binding of Hsp90 co-
chaperones and the Hsp90 inhibitor, PU-H71.  
Execution of Aim 2 will begin by making fluorescent and affinity–tagged Hsp90 wild-type 
and Hsp90 mutants in mammalian expression vectors. The mutations will either mimic or abolish 
Hsp90 phosphorylation identified in Aim 1. Glutamate substitutions will be used as 
phosphomimetics. Alanine and proline substitutions will be used as phosphorylation-null 
mutants, unable to be phosphorylated. Transfection of the Hsp90 expression vectors into mouse 
embryonic stem cells (E14 cell line) will allow for expression of the Hsp90 protein with its 
corresponding mutation. Using confocal microscopy, immunoprecipitation (IP), and western 
blotting techniques, I can analyze the effect of Hsp90 PTMs on regulating its interaction with 
Hsp90 co-chaperones. Co-chaperones are recruited to different stages in the Hsp90 chaperone 
cycle, and their abundance in the complexes of wild type Hsp90 and PTM mutants generated will 
be assessed. In addition to revealing how Hsp90 PTMs regulate the chaperone complex 
assembly, in conjunction with Aim 2, the results will elucidate how the Hsp90 conformational 




INTRODUCTION TO HSP90 
 
I. Hsp90 Background and Evolution 
Cells are constantly in a struggle to survive against internal and external stresses. Often, 
when exposed to a stress, the cell responds accordingly by altering the expression of its proteome 
to counteract the stress and maintain cellular proteostasis. For instance, during thermal stress, or 
heat stress, the expression of a protein known as heat shock protein 90 (Hsp90) is significantly 
increased1. Originally discovered due to its elevated expression in response to heat shock, Hsp90 
is now known as a prominent molecular chaperone protein responsible for organizing the 
interaction of a multitude of client proteins. Together with other molecular chaperones, Hsp90 
regulates the conformations of substrate proteins, collectively called clients, to aid in proper 
folder to prevent aggregation and also enable complex assembly, function activation, and ligand 
binding, all of which provide much needed adaptations toward stressful conditions and maintain 
cellular homeostasis. As a molecular chaperone, Hsp90 is one of the most abundant cytosolic 
proteins, whose expression is not only high during thermal stress but also during normal 
physiological conditions2.  
Lower organisms, such as bacteria, utilize an Hsp90 analogue, high temperature protein G 
(htpG)3, primarily for its ability to prevent protein aggregation induced by heat shock. 
Eukaryotes utilize Hsp90 for its function as a dynamic molecular chaperone, capable of 
reversibly binding many cofactors and regulate hundreds of proteins important in various cellular 
pathways. Unlike bacteria, which generally have a single Hsp90 homologue (htpG), eukaryotes 
have multiple Hsp90 genes that code for proteins in the cytosol, endoplasmic reticulum, and 
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mitochondria4. In the cytosol, Hsp90 exists as two major isoforms: Hsp90α, inducible by thermal 
stress, and Hsp90ß, constitutively expressed3,4.  Furthermore, Hsp90 molecular chaperones in 
eukaryotes function together with co-chaperones, which assist in client protein folding and 
activation.  
II. Hsp90 Structure and Conformational Cycle 
Hsp90 exists as a homodimer, and dimerization is required for its chaperone function5. Each 
monomer contains three distinct domains: an N-terminal domain (NTD), a middle domain (MD), 
and a C-terminal domain (CTD). There also exist regions between the three main domains such 
as the charged linker and MEEVD site. Between the NTD and MD is a charged linker region, 
which is flexible to allow conformational changes of Hsp90 and modulate domain interactions6. 
Following the CTD is a sequence of highly conserved amino acids, MEEVD, which serve as an 
interaction site for many co-chaperones7. Overall, the NTD plays a role in ATP binding and 
hydrolysis, as well as providing a second dimerization site between monomers8. The MD plays a 
role in ATP hydrolysis through interaction with the NTD and serves as an interaction site for 
many client proteins2. Lastly, the CTD provides the primary dimerization site between two 
Hsp90 monomers and the interaction site with client proteins, similar to the MD9. 
Each of the three Hsp90 domains have been associated with specific roles relevant to 
Hsp90’s functional and conformational cycle (Fig. 1). The NTD contains a component known as 
the “lid,” which helps to physically keep ATP  bound within the NTD for hydrolysis10. Binding 
of ATP to the NTD causes a conformational shift of the entire dimer, including the NTD/MD 
and MD/CTD interfaces within the monomer, along with rearrangements of the “lid” structure of 
the NTD. The lid is arranged in an “open” conformation when Hsp90 is bound to ADP, while it 




Figure 1: Hsp90 diagram displaying two dimerized Hsp90 monomers. Each monomer consists 
of a lid to cover the ATP binding pocket of the N-terminal domain (NTD), which is connected to 
the middle domain (MD) by a charged linker region. Following the MD is the C-terminal domain 
(CTD), which contains a five amino acid motif: Met-Glu-Glu-Val-Asp (MEEVD). Figure adapted 
from Schopf et. al. 2017.   
 
The chaperone functional cycle of Hsp90 is coupled to its conformational cycle and is 
primarily regulated by ATP binding (Fig. 2). In the conformational cycle, Hsp90 exists in an 
open, closed, or intermediate conformation. In the open conformation, Hsp90 has an unoccupied 
ATP-binding domain, the CTD’s of each monomer interact with each other to form a dimer. 
When ATP binds to the NTD of Hsp90, the lid of the NTD closes over the ATP molecule to 
facilitate a transition into the intermediate state. During the transition, the NTDs of the 
monomers interact, in which the Hsp90 dimer enters “closed 1 state.” Following NTD interaction 
between the monomers, the monomers twist together to generate the “closed 2 state,” in which 
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the MDs of each monomer interact. Once in closed 2 state, ATP hydrolysis occurs, as ADP and 
inorganic phosphate (Pi) are released. Finally, the NTDs separate, and Hsp90 returns to its open 
conformation to repeat the cycle2,13.  
 
III. Hsp90 Co-Chaperones 
Co-chaperones are proteins that interact with another chaperone protein, to enable the 
chaperone to fulfill its function. Currently, Hsp90 co-chaperones have only been identified in 
cytosolic Hsp90 and endoplasmic reticulum Hsp90s but not in bacteria or mitochondrial 
Hsp9014. The co-chaperones of cytosolic Hsp90 can be grouped based on their interacting 
domain with Hsp90. Most known co-chaperones of Hsp90 contain a tetratricopeptide repeat 
(TPR) motif, which is a 34-residue structural motif that forms several alpha helices. The TPR 
motif binds primarily to the MEEVD structure following the CTD of Hsp9015,16. Co-chaperones 
without a TPR motif bind to Hsp90 at its other domains, including the NTD, MD, and CTD2. 
 Known Hsp90 co-chaperones with a TPR motif include HOP, PP5, and CHIP. 
Hsp70/Hsp90-organizing protein (HOP) aids in transferring clients from Hsp70-Hsp40 complex 
to Hsp90, and it can also non-competitively inhibit ATPase activity in Hsp90 through interaction 
with the MD and CTD to keep Hsp90 in the open conformation. Serine/Threonine protein 
phosphatase 5 (PP5) dephosphorylates Hsp90 as well as its client proteins. Dephosphorylation 
plays a role in the conformational cycle of Hsp90 and the development of its client proteins. C-
terminus of Hsp70-interacting protein (CHIP) also has a TPR motif and has been associated with 
Hsp90-bound protein degradation. CHIP binds to Hsp90 at the MEEVD peptide, which triggers 




Figure 2: Hsp90 conformational cycle and association with selected co-chaperones. Beginning 
from the “Hsp90 Unbound State,” Hsp90 binds ATP in its NTD to enter the “Open ATP-Bound 
State.” Next, in the “Intermediate State,” the lid closes over ATP, so it does not leave the NTD. 
Following closure of the lid, the NTDs of each monomer associate with one another in the 
“Closed 1 State.” Finally, each monomer twists and associates with each other in the “Closed 2 
State.” ATP is hydrolyzed into ADP, and then the dimer returns to the “Unbound State,” and the 
cycle can begin again. Hsp90 co-chaperones have been associated with distinct conformational 
states in the cycle. HOP maintains Hsp90 in the open conformation, as it associates with Hsp90 
until the “Intermediate State.” CDC37 only associates with Hsp90 in the open conformations. 
PPIase associate with Hsp90 during each conformational state. Aha1 is associated with Hsp90 
in the “Closed 1 State,” while p23 is associated with Hsp90 in the “Closed 2 State.” Figure 
adapted from Schopf et. al. 2017. 
 
Co-chaperones without a TPR motif include CDC37, Aha1, and p23. Cell division cycle 37 
(CDC37) binds primarily to the lid of the Hp90 NTD to inhibit ATPase activity. Binding to the 
lid maintains Hsp90 in the open conformation and prevents NTD dimerization. CDC37 is also 
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involved in recruitment of protein kinase clients to Hsp9018. Activator of Hsp90 ATPase 
homologue 1 (Aha1) binds to the MD of Hsp90, but there is also evidence of it binding to the 
NTD. While bound to the MD, Aha1 activates Hsp90’s ATPase activity. Additionally, Aha1 
promotes the Hsp90 conformational cycle by forcing HOP out of the Hsp90 complex and 
interfering with client binding19. p23 is a co-chaperone necessary for maintaining Hsp90 in its 
closed 2 state through binding to a groove formed between the monomers of each NTD in the 
dimer. While stuck in the closed 2 conformation, Hsp90’s ATPase activity is lowered, as the 
release of ATP-hydrolysis products are delayed20.  
Table 1: Major co-chaperones of Hsp90 
Co-Chaperone Hsp90 Binding Site Function 
HOP MEEVD, MD, and CTD Transfers client proteins from 
Hsp70-Hsp40 to Hsp90 
PP5 MEEVD, MD, and CTD Dephosphorylates Hsp90 and 
clients 
CHIP MEEVD Facilitates Hsp90 degradation 
CDC37 NTD and MD Inhibits Hsp90 ATPase 
activity 
Aha1 NTD and MD Activates Hsp90 ATPase 
activity 
p23 NTD and MD Maintains Hsp90 in closed 2 
state 
Abbreviations: HOP, Hsp70/Hsp90 organizing protein; PP5, serine/threonine protein 
phosphatase 5; CHIP, C-terminus of Hsp90 interacting protein; CDC37, cell division cycle 37; 
Aha1, activator of Hsp90 ATPase homologue 1 
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Co-chaperones selectively bind to Hsp90 in a specific conformational state, yet many co-
chaperones share the same binding site on Hsp90. Consequently, each co-chaperone must 
associate and dissociate with Hsp90 so that the next co-chaperone can facilitate the progression 
of Hsp90 conformational cycle. Beginning in the open conformation, HOP binds to Hsp90 to 
inhibit ATPase activity. HOP may bind to Hsp90 with Hsp70 still associated with HOP21. Once 
HOP is bound, a peptidyl-prolyl cis-trans isomerase (PPIase) binds to the MEEVD domain 
through its TPR motif to generate an asymmetrical Hsp90 complex. To displace HOP, Aha1 or 
another PPIase with p23 binds to Hsp90. ATP binding in the NTD of Hsp90 facilitates the 
transition of Hsp90 from the closed 1 to closed 2 state. During the transition, p23 competes with 
Aha1 for binding of Hsp90 until it stabilizes in the closed 2 state. Once in the closed 2 state, ATP 
is hydrolyzed, and the products (ADP and Pi) are released along with the remaining co-
chaperones and clients. The cycle can then restart for another round of ATP hydrolysis22. 
CDC37, although a well understood Hsp90 co-chaperone, is primarily associated with protein 
kinases that are clients of Hsp90. It helps bring kinases to Hsp9023.        
 
IV. Hsp90 Clients 
Hsp90 is a highly promiscuous chaperone protein with hundreds of client proteins. As a 
result, Hsp90 plays a role in a plethora of cellular processes, including but not limited to heat 
stress response, protein homeostasis, DNA repair, immune response, and development. Most of 
Hsp90’s clientele can be classified into three groups (Table 2). The first group includes 
substrates, such as kinases, whose conformation is changed to enable activation. For example, 
the client kinase CDK4, interacts closely with an Hsp90-CDC37 complex, in which CDC37 
associates with both Hsp90 and CDK4 to stabilize the CDK4 in an open conformation. Hsp90 
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clamps onto the kinase helps stabilize its conformation from an unfolded state24. The second 
group includes substrates that require Hsp90 for their assembly into a multimeric protein 
complex, such as the Rvb1-Rvb2-Tah1-Pih1 (R2TP) complex. For the R2TP complex, Hsp90 
directly binds to Tah1 through a TPR motif, which aids in stabilizing the multimeric complex of 
proteins25. The third group includes substrates whose conformation is stabilized through Hsp90 
to allow for binding of another ligand to this stabilized conformation. An example of the third 
group includes the binding of a steroid hormone to a steroid hormone receptor (SHR). In this 
instance, Hsp90 in the closed state has been found to preferentially bind to a SHR to allow for 
later binding of ligands to the SHR26.  
Table 2: Representative client proteins of Hsp90 
Client  Function Disease 
Steroid Hormone Receptors   
Glucocorticoid Receptor Response to glucocorticoids Cushing Syndrome 
Progesterone Receptor Response to progesterone Cancer 
Kinases   
CDK Cell cycle control Cancer 
JAK1 and/or JAK2 Cytokine signaling Cancer 
E3 Ubiquitin Ligases   
MDM2 p53 degradation Cancer 
UHRF1 Embryonic development Cancer 
Transcription Factors    
p53 Tumor suppression protein Cancer 
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OCT4 Embryonic development Cancer 
Others   
Calcineurin Immune response Rheumatoid Arthritis 
NLR proteins Innate immune response Inflammation  
RAD51 and/or RAD52 DNA repair Cancer 
Abbreviations: CDK, cyclin dependent kinase; JAK, Janus kinase; MDM2, mouse double minute 
2 homologue; NLR, NOD-like receptor; OCT4, octamer-binding protein 4; UHRF1, ubiquitin-
like PHD and RING finger domain-containing protein 1.  
 
V. Posttranslational Modifications 
Transcription and translation are basic mechanisms used by the cell to regulate protein 
abundance, activity, and function. In proteomics, structure is often the defining factor of a 
protein’s function. Posttranslational modifications (PTMs), are covalent modifications to amino 
acid residues, provide an additional mechanism to regulate protein function. PTMs include, but 
are not limited to, phosphorylation, acetylation, methylation, and ubiquitination. In mammals, 
phosphorylation primarily occurs on serine, threonine, and tyrosine residues; acetylation occurs 
on lysine residues; methylation occurs on lysine or arginine residues; and ubiquitination occurs 
on lysine residues27,28. Many modifications play a role in the activity and interaction of Hsp90 
with its clients and co-chaperones. For example, hyperacetylation on lysine residues causes 
Hsp90 to become unable to bind to its co-chaperone p232 .     
Among the possible posttranslational modifications on Hsp90, phosphorylation is most often 
detected. An updated compilation of the phosphorylation sites on Hsp90, and other proteins, is 
located in the PhosphoSitePlus database (http://www.phosphosite.org)27. While numerous 
phosphorylated residues have been identified on Hsp90, the identity of enzymes which catalyze 
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the phosphorylation remains largely unknown29. Phosphorylation of Hsp90 has been reported to 
alter the conformation of Hsp90 and regulate its interaction with clients and co-chaperones. For 
instance, protein kinase A (PKA)-mediated phosphorylation of Hsp90 on Thr-89 releases 
androgen receptor (AR) from Hsp90, enabling AR transactivation and cell proliferation30. Hsp90 
phosphorylation at Y197 regulates its interaction with Cdc37 and provides client specificity for 
kinases31. In addition, phosphorylation not only regulates client and co-chaperone binding, but 
also enables allosteric communication between domains within the Hsp90 dimer2. Further insight 
into the structural and conformational changes caused by PTMs will generate a better 
understanding of Hsp90’s function and regulation.    
VI. Protein Identification Through Mass Spectrometry 
In the field of proteomics, mass spectrometers have become a central tool for studying 
proteins and their modifications. Through advances in mass spectrometry (MS), proteins can be 
effectively identified and quantified. Usually, protonated biomolecules are moved in the highly 
sophisticated electric fields of a mass spectrometer for an accurate measurement of their 
molecular weight. A mass spectrometer can also energetically, through collisions with inert 
molecules, or chemically, through electron deposition, induce backbone fragmentation of 
biomolecules and measure the molecular weight of generated fragments. Using molecular weight 
information of biomolecules and their fragments, the chemical structure of measured 
biomolecules can be elucidated through database search using bioinformatic software. Since the 
transmission of peptides is more effective than large-size proteins in the electric field of a mass 
spectrometer, proteins are often proteolyzed into peptides for MS analysis. Trypsin is often the 
preferred protease because it cleaves proteins at the C-terminal end of Lys and Arg residues and 
uniformly introduces a positive charge at the C-terminus of tryptic peptides for MS analysis. 
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Mass spectrometry is not an intrinsically quantitative technology. Peptides of different amino 
acid sequence give different MS ion intensity, even when equal molar numbers of peptides are 
analyzed. In addition, higher abundance peptides can suppress the detection of lower abundance 
peptides due to the limited dynamic range of most mass analyzers. Therefore, upstream 
fractionation of peptide or protein samples can potentially increase dynamic range and facilitate 
the detection of low abundance species. Reverses-phase high-performance liquid 
chromatography (RP-HPLC) utilized highly volatile solvent components that are compatible 
with MS analysis, thus is often coupled online with mass spectrometers and increase the dynamic 
range of peptide detection by two magnitudes. Tryptic peptides are separated by their 
hydrophobicity on RP-HPLC columns, then introduced to the mass spectrometer by an 
electrospray ion source, where protonated peptides are aerosolized, desolvated, and transitioned 
to the gas phase. 
For mass spectrometry-based proteomic analysis, the mass spectrometer alternates between 
the MS and MS/MS mode for data acquisition. In MS mode, peptides eluting from the LC will 
be sent to the major mass analyzer to measure their peptide mass and ion intensity. In MS/MS 
mode of data-dependent acquisition, only peptides with pre-selected mass (often on of the high 
abundance peptides) will have a stable trajectory and undergo fragmentation for fragment mass 
measurements. Peptide fragmentation usually takes place at the peptide backbone. In collision- 
induced dissociation (CID), peptide amide bonds are the preferred cleavage sites, generating the 
N-terminus containing b-ions and the C-terminus containing y-ions. For tryptic peptides, the C-
terminal Lys and Arg residues are basic and often protonated, thus giving strong y-ion series.  
The acquired LC/MS and MS/MS data will be processed to extract the peptide and fragment 
masses for bioinformatic analysis. Protein database search applies two criteria. First, the peptide 
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masses will be searched against the in silico proteolytic peptide library of protein entries in the 
database, and the matched peptide entries within a specified error window will be selected. 
Secondly, the acquired fragment masses of the peptide will be matched to the in-silico fragments 
of candidate peptides. Candidate peptides will be scored based on how well their fragment 
masses match to the measured fragment masses, and the well-matched entries (together with 
proteins where the matched peptides are from) will be reported if their score passes the threshold 
score. To assess the confidence of database search results, false discovery rate will be calculated 
using a concatenated database with decoy half made of protein entries with randomized amino 
acid sequences. Posttranslational modifications are analyzed in a similar fashion, with all 
possible peptides with specified modifications included in the in silico peptide library32. 
 
VII. Uses of Chemical Cross-linking and Mass Spectrometric Analysis (CXMS) 
Chemical cross-linking is a technique often utilized to covalently stabilize dynamic 
interactions, by bifunctional chemical cross-linkers. The side-chain of two amino acids can react 
with the two functional groups of a cross-linker and covalently link together when they are in 
spatial proximity. Although the amino acids may not be close in primary structure, they may be 
close in space due to the protein’s tertiary structure. The following mass spectrometric analysis 
of the cross-linked proteins and protein complexes can lead to identification of the cross-linked 
peptides. When used in conjunction with computational modeling, CXMS can generate medium-
resolution models of proteins and protein complexes32.  
Many studies have shown the robustness of chemical cross-linking as a method for providing 
structural information of proteins and protein complexes. Importantly, chemical cross-linking has 
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been found to minimally alter the structure of proteins, as cross-linking experiments conducted 
on enzymes such as human carbonic anhydrase I showed minimal changes in enzyme activity 
and nuclear magnetic resonance (NMR) chemical shifts33. Additionally, XM-MS analyses have 
generated results in good agreement with previously reported structures and elucidated novel 
structural information. For example, CXMS data used to generate a structural model of 
phosphodiesterase 6 (PDE6) agrees well with biochemical data spanning years of previous 
research, and revealed a novel open conformation of Pαß catalytic dimer, which was later 
validated by two independent EM studies34. Other examples include studies to identify the 
oligomerization interface of a viral double-stranded RNA receptor (MDA5)35, and the eukaryotic 
unfolded protein response sensor IRE136. Mutations introduced at the oligomerization interface 
identified by CXMS analysis disrupted filament formation in vitro and abolished the activity of 
MDA5 and IRE1 in vivo. 
Due to the reliability of CXMS as an accurate model for determining protein structures, 
CXMS has become an attractive method for studying complex systems ranging from protein 
systems with multiple conformation states to multimeric protein complexes. Advances in 
bioinformatics have also increased the throughput of CXMS data, allowing for faster and more 
reliable data analysis37.  Examples of protein complexes studied using CXMS include the 26S 
proteasome complex38, the chromatin remodeling complexes INO8039 and SWR140, the RNA 






VIII. Significance of Hsp90 Research and Posttranslational Modification Analysis 
Under the stressed state of cancer, cells rapidly divide and utilize a number of Hsp90 client 
proteins to promote tumor survival43. Furthermore, Hsp90 client proteins have been shown to be 
altered in cancer cells, including being overexpressed and/or mutated44. Studies show that in 
more than 50% of tumor cells Hsp90 exists in higher-order chaperone complexes, called the 
epichaperome45,46. The epichaperome, a term coined by the Chiosis Lab Group, refers to a stress-
induced, stable, multimeric, hyperconnected, and functional Hsp90-Hsc70 chaperome network. 
The epichaperome machinery includes Hsp90, Cdc37, HOP, Hsc70, Hsp110, and Aha1. Since 
not all tumors contain Hsp90 in the epichaperome, there exists nomenclature to differentiate 
tumors with and without the epichaperome. Tumors containing the epichaperome have been 
termed “type 1 tumors,” while tumors without the epichaperome have been termed “type 2 
tumors.” In type 1 tumors, it has been shown that the epichaperome is essential for tumor 
survival, as inhibition of the epichaperome via the inhibitor PU-H71 (PU) resulted in cell death. 
PU is an Hsp90 inhibitor with a strong affinity to Hsp90 when it is complexed with other co-
chaperones in the epichaperome conformation47. Despite advances in knowledge in Hsp90’s 
conformation in the epichaperome, there is still much to determine in terms of how Hsp90 is 
assembled into the epichaperome and what factors drive its formation and stabilization. With 
phosphorylation playing a key role in Hsp90 conformation and co-chaperone regulation48, it is 
possible that phosphorylation may play a role in epichaperome stabilization as well.   
In this proposed study, I hypothesize that posttranslational modifications (PTMs), 
specifically phosphorylation of Hsp90, regulate its conformation in the epichaperome and its 
interactions with other chaperone proteins. I will use techniques in mass spectrometry to 
15 
 
characterize the structure and PTMs of Hsp90 in the epichaperome to address fundamental 
questions on how Hsp90 chaperones are rewired in tumorigenesis.  
Successful determination of PTMs of Hsp90 can have broad impacts on the field of cancer 
research. In this study, phosphorylation is the PTM of interest, and determination of the impact 
of phosphorylation on Hsp90’s structure in the epichaperome, may have implications on its 
regulation and structure in cancer tumors. As cancer therapy moves towards more individualized 
treatment, it will be important to effectively treat the epichaperome if it is present in a patient. 
Insights in the structure of Hsp90 in the epichaperome will be essential for designing 
therapeutics to specifically target subpopulations of Hsp90 in tumor cells while minimizing 
cytotoxicity. Additionally, recent studies have linked the epichaperome to other diseases besides 
cancer, such as Parkinson’s Disease49. Therefore, insights into the epichaperome may be useful 

















CHARACTERIZATION OF HSP90 POPULATIONS TARGETED BY PU-H71 AND 
GELDANAMYCIN 
 
I. Hsp90 Inhibitors 
Within tumor cells, Hsp90 can be expressed at concentrations 2 to 10-fold higher when 
compared to other heat shock proteins. At these higher levels, Hsp90 can be hijacked to stabilize 
mutated and overexpressed oncoproteins, thus making Hsp90 an attractive therapeutic target in 
cancer50. Embryonic stem cells (ESCs) serve as a good model for cancer cells with an increased 
stress tolerance, as they show a similar dependence on Hsp90 with high levels of chaperone 
expression51. Exemplifying the importance of Hsp90 in ESCs, is the ability of the Hsp90 
inhibitor 17-AAG, a geldanamycin derivative to induce ESC differentiation and apoptosis at a 
concentration as low as 50nM52. 
 Since 1998, 18 chemically distinct Hsp90 inhibitors, natural products, and synthetic 
derivatives have entered clinical trials. Of these 18 inhibitors, all target the NTD of Hsp90, with 
5 in clinical trials as of 2018. One Hsp90 inhibitor, geldanamycin (GA), is a natural product 
antibiotic of the benzoquinone ansamycin class53, and its 2D structure is displayed in Figure 3. 
GA functions by binding to the ATP-binding pocket of the NTD of Hsp90, thus Hsp90 cannot 
shift from its ADP to ATP-bound conformations. The inability to switch between conformations 
leads to Hsp90 destabilization and client protein degradation via the proteasome. Despite being a 
promising Hsp90 inhibitor, GA was too toxic and unstable, as hepatotoxicity was reported, so it 




        
Figure 3: 2D structures of PU-H71 (PubChem CID #9549213) (A) and Geldanamycin 
(PubChem CID #5288382) (B) 
 
To address the toxicity issues of previous Hsp90 inhibitors, the National Cancer Institute 
and the Chiosis research group at Memorial Sloan-Kettering Cancer Center developed PU-H71 
(PU). PU differs from GA-inhibition of Hsp90, as PU is selective for Hsp90 in the epichaperome 
conformation, yet it also binds to the ATP-binding pocket of the NTD of Hsp90. PU’s 2D 
structure is shown in Figure 3. In clinical trials, PU was generally well received among patients 
tested, as there was a low incidence of adverse patient responses greater than grade 2. Only one 
instance of grade 3 toxicity occurred. Despite promising results in the clinic, the trial was 
stopped prematurely due to discontinuation of drug supply55.  
 Despite both GA and PU being stopped in clinical trials, they still serve as important 
tools for characterizing the structure and conformation of Hsp90 subpopulations. PU binds 
selectively to epichaperome Hsp90 in complex with co-chaperones and client proteins, while GA 
was thought to bind to un-complexed Hsp9056. To gain more insight into the Hsp90 populations 






performed on GA and PU bound Hsp90 in ESCs. Chemical cross-linking covalently binds two 
amino acid residues together, and through MS analysis, cross-linked peptides can be identified. 
Mapping these linked residues back to Hsp90 structures can elucidate the spatial organization of 
residues to characterize protein or protein complex structure and conformation32. Chemical 
cross-linking is described in Figure 4. Characterization of Hsp90 structures targeted by PU and 
GA can provide useful information for future drug design by describing their binding sites and 
preferred Hsp90 conformation. 
 
 
Figure 4: Chemical cross-linking and mass spectrometric analysis (CXMS) workflow used to 






II. Materials and Methods 
Mammalian cell culture and lysis 
 Mouse embryonic stem cells, E14 cell line, were grown in a 37°C incubator with an 
atmosphere containing 5% CO2. E14 cells were maintained with growth media composed of 
Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum, 2 mM L-glutamine, 1X non-
essential amino acids, 1x penicillin/streptomycin, beta-mercaptoethanol, and leukemia inhibitory 
factor. Growth surfaces were coated with 0.2% gelatin. Cells were grown for about 36-48 hours, 
or 70-80% confluency, then washed with phosphate buffered saline (PBS). Adherent cells were 
removed from growth surfaces using 0.05% trypsin-EDTA, resuspended with cell maintenance 
media, and pelleted. Cell pellets were resuspended in 1 mL of PBS then pelleted again at 6,000 
RCF. Pellets were flash-frozen in liquid nitrogen and stored in -80°C. 
Harvested pellets were resuspended in Felts lysis buffer (20mM HEPES pH 7.4, 50 mM 
KCl, 5 mM MgCl2, 0.01% NP-40) supplemented with protease, phosphatase, and deacetylase 
inhibitors. Resuspended pellets were sonicated on ice three times for 15 seconds, with 1 minute 
in between each sonication. The sonicated lysate was centrifuged at 13,000 RPM twice at 4°C 
and the protein-containing supernatant was transferred to a clean tube. Protein concentration was 







Cell lysates were cross-linked for 1 hour at room temperature using disuccinimidyl 
suberate (DSS) at a concentration of 2.5 mM. The reaction was quenched at room temperature by 
adding 5 μl of 0.8M NH4OH for 15 minutes. Lysates were cleared by two rounds of 
centrifugation at 13,000 RPM for 15 minutes at 4°C. Following centrifugation, Hsp90 was 
separated by immobilized PU-H71 or GA. 
 
GA and PU Chemical Precipitation 
 The immobilized GA-affinity beads were prepared by incubating GA-biotin (Sigma, 
SML0985) with Dynabeads M-280 Streptavidin (Thermo Fisher, 11205D) at 4°C for 2.5 hours 
while rotating. The GA-bound beads were then incubated with cross-linked cell lysates overnight 
at 4°C while rotating.  After incubation, the beads were washed three times with lysis buffer at 
4°C and eluted by boiling at 95°C with 1X SDS-PAGE sample buffer. 
The PU-affinity beads were obtained from Dr. Gabriella Chiosis’ lab. The cross-linked 
cell lysates were incubated with PU-H71 bound beads or control beads at 4°C for 3.5 hours. 
Following incubation, the complexed beads were washed three times in lysis buffer before 
elution by boiling at 95°C with 1X SDS-PAGE sample buffer. The chemical cross-linking and 
Hsp90 purification experiments were carried out in >3 replicates for both ligands. Samples were 






SDS-PAGE and Trypsin digestion 
 After elution from the immobilized beads, samples were loaded onto a 7.8% SDS-PAGE 
gel and only ran until the sample completely entered the separating gel. To visual proteins, the 
SDS-PAGE gel was stained in Coomassie Blue stain (0.1% Coomassie Brilliant Blue R250 
(wt./vol), 10% glacial acetic acid (vol/vol), 50% methanol (vol/vol)) then de-stained using a de-
stain solution (10% glacial acetic acid (vol/vol), 45% methanol (vol/vol), and 45% H2O).   
In-gel digestion was carried out as described previously (Chu et. al 2004)57. Briefly, in-
gel digestion began by excising the unseparated cross-linked Hsp90 complexes from the gel 
using a clean razor blade dicing them into small cubes. The diced gel cubes were placed in a 0.5 
mL maximum recovery tube. The small cubes were washed with 50 μL of 25 mM 
NH4HCO3/50% acetonitrile (ACN) and vortexed for 10 minutes. After each vortex, the 
supernatant was discarded, and the step was repeated for three total washes. Next, the sample 
was reduced using 100 μL 10mM DTT (in 25mM NH4HCO3) at 56°C for 1 hour. After 
incubation, the supernatant was discarded. Next, the gel pieces were alkylated with 100 μL of 55 
mM iodoacetamide (in 25 mM NH4HCO3) in darkness for 45 minutes. Again, the supernatant 
was discarded following incubation. Gel pieces were then washed with 25 mM NH4HCO3. Next, 
the pieces were dehydrated by washing three times with 25 mM NH4HCO3/50% ACN (vol/vol) 
then completely dried using a speed-vacuum at room temperature. Dried gel pieces were 
proteolytically digested using various trypsin volumes ranging from 15-25 μl. The trypsin was 
prepared by mixing 10 µL of 0.5 mg/mL trypsin (Promega Part #V5113) in 90 µL of 25mM 
NH4HCO3. The lowest intensity bands received 15 μl of trypsin in 25 mM NH4HCO3, while the 
highest intensity bands received 25 μl. Trypsin digestion was carried out at 37°C for 4 hours. 
Following digestion, tryptic peptides were extracted twice by vortexing for 20 minutes with 35 
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μL extraction buffer (50% ACN (vol/vol)/2% acetic acid (vol/vol). The extracted peptides were 
transferred to a clean tube and brought down to 3.5 μL using a speed-vacuum. The concentrated 
sample was brought up to a final volume of 7 μL with 0.1% formic acid.   
 
Qualitative and Quantitative Mass Spectrometry Data Analysis 
Briefly, 1μl aliquot of the digestion mixture was injected into a Dionex Ultimate 3000 
RSLCnano UHPLC system (Dionex Corporation, Sunnyvale, CA), and separated by a 75 μm × 
25 cm PepMap RSLC column (100 Å, 2 μm) at a flow rate of ~450 nL/min. The eluant was 
connected directly to a nanoelectrospray ionization source of an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, Waltham, MA). LC-MS data was acquired in an information-
dependent acquisition mode, cycling between a MS scan (m/z 315–2,000) acquired in the 
Orbitrap, followed by low-energy CID analysis on three most intense multiply charged 
precursors acquired in the linear ion trap. 
Cross-linked peptides were identified using an integrated module in Protein Prospector, 
based on a bioinformation strategy developed in the UCSF Mass Spectrometry Facility. Key 
cross-linked peptides were identified and confirmed by manually examining the returned 
spectrum, peptide scores and mass accuracy. Cross-linked peptides identified from various 
samples were pooled together, and the cross-linked percentage for each peptide pair was 
calculated using the following formula: 
%𝑋𝐿 =
𝐶𝑟𝑜𝑠𝑠𝑙𝑖𝑛𝑘𝑒𝑑 𝑃𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑒𝑎𝑘 𝐻𝑒𝑖𝑔ℎ𝑡 (𝑃𝐻) 




 In the formula, peak height is the apex peak height in LC-MS/MS runs, and dead-end 
XLs were cross-linker modified, where only one NHS-ester function of DSS was cross-linked to 
a Lys residue and the other NHS-ester function was hydrolyzed by water. 
 
Homology Modeling 
Mouse Hsp90 alpha and beta isoform sequences were aligned, and the models were built 
using an open conformation template (PDB 2IOQ), a closed conformation template (PDB 
2CG9), and an Hsp70-bound model (derived from a cryo-EM structure of Hsp90•Hsp70•GR 
complex) using UCSF Modeller. Structural visualization and analysis were carried out using 
UCSF Chimera (https://www.cgl.ucsf.edu/chimera/). 
 
III. Results and Discussion 
 
PU-H71 and GA target distinct subpopulations of Hsp90 complexes 
 To purify Hsp90 targeted by PU-H71 and GA, resin immobilized with PU and GA (see 
Materials and Methods, p.26) was used and chemical precipitation experiments were carried out 
under similar conditions described previously46. Similar, to the previous study, PU-H71 showed 
a high affinity towards Hsp90 in multi-subunit, high-order complexes (Fig. 5A., PU-H71 pull-
down lane). Control resins coated with polyamines did not purify any protein complexes (Fig. 
5A, control lane), thus displaying the how the interaction between PU-H71 and Hsp90 are 
specific. GA-bound resin also precipitated a substantial amount of Hsp90; however, the elution 
contained much less co-purifying proteins (Fig. 5B), which is consistent with previously 
established notion that GA binds to uncomplexed Hsp9056. 
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 To characterize the protein components that co-precipitated with PU-H71 and GA-bound 
Hsp90, each PU-H71 and GA chemical precipitation lane was excised into 12 sections and LC-
MS/MS was used to identify and quantity proteins associated with PU-H71 and GA-coated 
resins. A semi-quantitative, spectra-counting method58,59 was used to compare the amount of 
proteins precipitated by PU-H71 or GA (Table 3). Unsurprisingly, cytosolic Hsp90α and Hsp90ß 
along with Hsp90’s mitochondrial analogue, Trap1, returned as the top proteins in the chemical 
precipitation. Using discriminant peptides that distinguish Hsp90α from Hsp90ß, the amount of 
Hsp90α and Hsp90ß purified by either PU or GA was compared. One of the discriminant peptide 
pairs, 88T-K100 in Hsp90α and 83T-K95 in Hsp90β, differs by only a single amino acid (Ile in 
Hsp90α and Leu in Hsp90ß), thus isobaric, or equal, in peptide mass. Extracted ion 
chromatograms of the discriminant peptides’ mass showed a ratio of about 1.5 Hsp90ß/Hsp90α 
in the ESC lysate and PU pulldown (PD) samples. In the GA PD sample, there was a ratio of 
about 1.0 Hsp90ß/Hsp90α (Fig. 5C). Together, the extracted ion chromatography results suggest 
that GA preferentially binds to Hsp90α, while PU binds in an unbiased manner with either 
cytosolic Hsp90 isoform. Additionally, Hsp90ß verses Hsp90α binding preferences were 
assessed using spectra counting (708/540 = 1.31 for PU PD; 219/235 = 0.93 for GA PD) and 
found results displaying ratios consistent with discriminant peptides, validating spectra counting 
as a quantitation method.   
 Next Hsp90α was used to normalize protein loading in PU and GA PDs and examined the 
enrichment or depletion of Hsp90 co-chaperones and client proteins in each PD (Table 3). In 
agreement with a previous study, PU bound Hsp90 existed in an Hsc70-nucleated multi-subunit 
complex, referred to as the epichaperome46. Quantitative comparison of co-chaperone abundance 
in both PDs suggested that GA targets a subpopulation of Hsp90 in which Hsp90 exists in an 
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early, or open conformation in its conformational cycle, as Hsp90 preferentially interacts with 
Hsc70 and Stil/Hop1. In the PU PD, results suggested that Hsp90 exists in a later, or closed 
conformation in its conformational cycle, as Hsp90 associates with Ahsa1, a co-chaperone that 
activates Hsp90 ATPase activity. Furthermore, PU bound complexes included several co-
chaperones whose functions are specific for different clients, including Cdc37 for client kinases, 
Sgt1 for client E3 ligases, and Plk1 for client chromatin proteins. 
 To further indicate PU targeted a later stage in the chaperone cycle, it was observed there 
were many client proteins associated with the PU bound complexes. Table 3 displays many 
Hsp90 client proteins with higher abundance in the PU PD than the GA PD. Clients include 
Trip12 and Ubr2, which are ubiquitin E3 ligases, and Stat3 and Brat1, which are kinases 
essential in signal transduction and cell cycle regulation. Another client is the transcription factor 
Oct4, an important member of the transcriptional machinery that regulates ESC pluripotency and 
self-renewal. Dysregulation of Oct4 through Hsp90 inhibition leads to ESC differentiation and 
cell death. Another client is the transcription activator protein Pur-alpha (PurA), which 
specifically binds to the purine-rich single strand of the PUR element located upstream of the 
MYC gene. The MYC gene is upregulated in ESCs and PU-H71 sensitive tumors. The presence 
of PurA in PU bound complexes suggests that the cytotoxicity of PU in c-Myc (+) tumor cells is 









Figure 5: Purification of Hsp90 subpopulations using PU-H71 and GA-immobilized beads. (A) 
SDS-PAGE of pull-down (PD) samples using PU-H71 (A) or GA immobilized beads (B). (C) 
Extracted ion chromatogram of an isobaric, discriminant peptide pair from ESC lysate sample, 

























Table 3. Proteins purified by immobilized PU-H71 or geldanamycin 
Proteins 
# of MS/MS spectra in 
PU-H71 pull-down 
# of MS/MS spectra 
in GA pull-down 
PU-H71/GAa 
Hsp90 540 235 1.0 
Hsp90 708 218 1.4 
Trap1 84 14 2.6 
Co-chaperones:    
Hsc70 56 68 0.4 
BiP 13 18 0.3 
Sti1/Hop1 38 3 5.5 
FKBP4 56 2 12.2 
Tpr2 20 -- High 
Aha1 17 -- High 
Cdc37 8 -- High 
Tom70 10 -- High 
Sgt1 8 -- High 
Stub1 9 -- High 
Substrates:    
Trip12 20 -- High 
Ubr2 37 -- High 
Mapk1 33 -- High 
Mapk14 13 -- High 
Mapk9 15 -- High 
CKII 27 -- High 
Cdk1 4 -- High 
Cdk9 2 -- High 
G 8 -- High 
Plk1 3 2 0.7 
mTor 3 -- High 
Hdac6 9 1 3.9 
Stat3 14 -- High 
Esrrb 4 -- High 
Brat1 6 -- High 
PurA 6 -- High 
Oct4 2 -- High 
aRatio of the MS/MS spectra number for proteins purified by PU-H71 or geldanamycin (GA) resin. Hsp90 was 
used to normalize the protein loading for the pull-down experiments. The ratio is exclusive to the PU pulldown, as 
many proteins were not reported in the GA pulldowns 
 
PU-H71 and GA target subpopulations of Hsp90 in distinct posttranslational modification states 
 Analysis of the PU PD samples also revealed several peptides with phosphorylation on 
Ser226 and Ser255 of Hsp90ß (Fig. 6A, 4B), corresponding to Ser231 and Ser263 of Hsp90α. 
MS/MS spectra (S226Hsp90ß peptide in Fig. 6A; S255Hsp90ß peptide in Fig. 6B) together with high 
mass accuracy led to conclusive identification of the peptide sequence and phosphorylation site. 
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Both phosphorylated S226 and S255 peptides did not exist in substantial quantity in the GA PD 
samples, suggesting that PU and GA likely target Hsp90 subpopulations in distinct 
posttranslational modification states. No phosphopeptides containing Y197Hsp90α were identified 
as was previously reported56. Although, there was a high abundance of Y197Hsp90α-containing 
unmodified peptides detected, its presence cannot be ruled out due to the often low abundance of 
tyrosine phosphorylation levels. 
 Next, the ion intensity was compared of these phosphopeptides in Hsp90 purified by PU 
immobilized beads with bulk Hsp90 in ESC lysates. In the comparison, there was significant 
enrichment detected of these phosphopeptides in PU PDs. The phosphorylated S255Hsp90ß peptide 
in PU PDs (Fig. 6C. left panel, red) is nearly six times more abundant than that in ESC lysate 
samples (Fig. 6C, left panel, black). A representative tryptic peptide in PU PDs (Fig. 6C, right 
panel, blue) is about three times more abundant than that in ESC lysate samples (Fig. 6C, right 
panel, black). In relation to Hsp90’s structure, residues S226/S255Hsp90ß localized to a highly 
charged linker that regulates the interactions of Hsp90 with co-chaperones and client proteins6. 
The high phosphorylation levels and enrichment of S226 and S255 in PU PDs targeting the 
epichaperome implicate a possible role of the residues in stabilizing Hsp90 in a conformation 






Figure 6: Phosphorylation of the Hsp90 charged linker region. Tandem MS spectra of Hsp90β 
Ser226 (A) and Ser255 (B) phosphorylated peptide provide conclusive information on the 
sequence and phosphorylation site of the peptides. (C) Extracted ion chromatogram of Hsp90β 
Ser255 phosphopeptide in PU-H71 PD (red trace, left panel) or ESC lysate (black trace, left 
panel) samples; and a representative unmodified tryptic peptide in PU-H71 PD (red trace, right 




PU-H71 and GA target subpopulations of Hsp90 in distinct conformational states 
 To further characterize the conformational states of Hsp90 subpopulations targeted by PU 
and GA, chemical crosslinking was performed by treating the mouse ESC lysates with 
disuccinimidyl suberate (DSS), an amine reactive, bifunctional crosslinker. After crosslinking, 
Hsp90 and its associating proteins were purified by PU or GA-immobilized beads. Crosslinking 
serves as a powerful tool to obtain structural information on a protein, as the crosslinker 
covalently links two lysine residues that are close in spatial proximity. Crosslinked lysine 
residues can be identified by tryptic digestion followed by liquid chromatography and MS 
analysis(LC-MS/MS)32. Furthermore, crosslinking propensity, or likelihood to be crosslinked, is 
determined by quantitative analysis of crosslinked products can provide useful information on 
changes in structural conformation or conformational equilibrium60. To compare crosslinking 
propensity, the crosslinking percentage of each crosslinked pair was calculated, normalizing the 
MS ion intensity of crosslinked peptides by the sum of all crosslinked peptides and crosslinker 
modified peptides that contained the crosslinked residues (Table 4). Normalizing the MS ion 
intensity minimizes the effects of large variation in the reactivity of crosslinked residues. 
Minimization of variation allows for the crosslinking percentage off each crosslinked pair to be 










Table 4: Cross-linking propensity of PU-H71 and GA-bound Hsp90 





Hsp90:      
58 112 86.75.7 66.910.5 15.8c 20.9d 
293 363 26.12.8 12.02.3 16.5 13.9 
295 363 9.80.9 7.11.7 --- --- 
408 415 22.32.3 16.51.0 11.3 11.0 
408 419 26.92.9 23.92.5 17.3 17.3 
411 415 29.51.1 24.01.0 6.4 6.4 
411 419 16.20.9 13.72.7 12.4 12.7 
444 616 16.40.7 3.50.1 20.7 29.0 
459 415 5.31.4 6.02.3 13.3 13.3 
586 566 40.519.8 40.121.1 14.0 16.2 
616 633 15.12.5 10.81.1 16.2 17.5 
Hsp90:      
53 107 88.46.2 66.07.7 15.8c 20.9d 
399 410 28.92.5 25.81.8 17.2 17.3 
399 406 23.12.5 17.11.2 11.2 11.0 
402 406 22.81.2 20.01.1 6.4 6.4 
402 410 20.4.11.0 19.12.9 12.4 12.7 
435 347 27.88.5 14.43.7 17.8 16.1 
435 607 9.00.4 3.92.8 20.3 29.0 
577 557 50.015.5 50.64.9 13.9 16.2 
624 607 36.82.7 31.47.4 16.1 17.5 
623 568 29.79.5 2.534.3 14.0 14.7 
aDistance measured from a model built from PDB structure 2CG9; bDistance measured from a model of 
Hsp90•Hsp70•GR complex derived from a cryo-EM density map; cDistance measured from a Trap1•PU-H71 
complex model (PDB 4Z1F); dDistance measured from a Hsp90•GA complex model (PDB 1YET). 
 
Next, the cross-linking percentage was measured of cross-linked pairs from PU and GA-
bound Hsp90 subpopulations and compared their cross-linking propensities (Fig. 7A). If PU and 
GA-bound Hsp90 had an equal likelihood for crosslinking, meaning a similar conformation, then 
the data points would evenly distribute along a straight line with a slope of 1 (Fig. 7A, blue 
dotted line). Figure 7A shows most of the data points arranged near the dotted line, suggesting a 
similarity in PU and GA-bound Hsp90 complexes. However, there were a few outlying cross-
linked residues (Fig. 7A, orange dots) that indicated conformational differences between the PU 

























Figure 7: Difference in cross-linking propensity reveals distinct conformational states targeted 
by PH-H71 and GA. (A) Average cross-linking percentage of PU-H71 (x-axis) and GA (y-axis) 
bound Hsp90 cross-linked pairs were plotted. A straight line (dotted) with a slope of 1 indicates 
18 pairs with similar cross-linking propensity. Outliers with statistical significance in >3 
replicate measurements were marked as solid orange dots. Outliers without statistical 
significance in replicates were marked as orange circles. (B) GA and PU-H71 binds to NTD in 
different modes. (C) The distance between the Cα of Lys444α and Lys616α is shorter in closed-
like conformation than the open-like conformation. (D) Ligand binding in NTD affects 
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ATP binding pocket in Hsp90α and Hsp90ß’s NTD, which were Lys58α-Lys112α and Lys53ß-
Lys107ß. The cross-linking percentages (Table 4) displayed that in both Hsp90α and Hsp90ß 
there was a higher cross-lining percentage in PU-H71 (87%α and 88%ß) than GA-bound (67%α 
and 66%ß) Hsp90 subpopulations. Despite both inhibitors binding to Hsp90’s hydrophobic 
pocket in the NTD, each inhibitor organizes the ATP lid differently (Fig. 7B). The bulkier GA 
binds shallowly to the pocket, positioning helix 6 and 7 away from the nucleotide binding site61 
and preventing full closure of the ATP lid. Though the corresponding region is missing in the 
crystal structure of the Hsp90•PU-H71 complex (PDB 4Z1F)62, PU binds deeply in the pocket, 
thus allows this region to pack against helix 4 and positions Lys112α/Lys107β more closely to 
Lys58α/Lys53β, similarly to the closed structure of Hsp90 (PDB 2CG9)10. This notion is 
consistent with the higher cross-linking propensity observed in PU-bound Hsp90 (Table 4). 
Another outlier in cross-linked pairs (Fig. 7A) involves Lys444α, found in the MD of 
Hsp90, and Lys616α, found in the CTD. Lys444α is localized in the middle of the MD, while 
Lys616α is localized to a helix near the central axis of the Hsp90 homodimer. Since the residues 
are found in different domains, the distance between Lys444α and Lys616α (20 Å in closed-like, 
ATP-bound conformation; 29 Å in V-shaped, open-like conformation) can indicate the relative 
placement of the monomer arms in Hsp90 conformations. With a linker arm length of 11.4 Å, the 
cross-linker (DSS) can span up to ~30 Å between the Cα of cross-linked residues. The low cross-
linking percentage of Lys444α and Lys616α detected in GA-bound Hsp90 suggests a long 
distance (29 Å) between the Cα of Lys444α and Lys616α. The long distance between residues 
could indicate Hsp90 adopts an open-like conformation when bound to GA. This V-shape, open-
like conformation is not only observed in a crystal structure of apo Hsp9063, but also in a cryo-
EM structure of Hsp90•Hsp70•GR complex64. In this study, there was detected an enrichment of 
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Hsp70 binding and open-like conformation in GA-bound Hsp90 subpopulation. Meanwhile, a 
medium cross-linking percentage of Lys444α and Lys616α was detected in PU-bound Hsp90. 
The medium distance (20 Å) between the Cα of Lys444α and Lys616α could indicated that PU-
bound Hsp90 adopts a closed-like conformation (Fig. 7C). Similarly, a significantly higher cross-
linking percentage was also observed in the corresponding Lys pair in the Hsp90β isoform 
(Lys435β-Lys607β), suggesting the results in the Hsp90α isoform are comparable in the Hsp90ß 
isoform.  
 The third outliers involve the cross-linked residues Lys293α and Lys363, located near the 
interface of the NTD and MD, which is sensitive toward the ATP binding site in the NTD. 
Ligand binding significantly affects the NTD and induces a relative rotation between the NTD 
and MD. Such conformational changes reposition the relative location of secondary structures at 
the NTD/MD interface, altering the distance between Lys293α and Lys363α (Fig. 7D). As 
expected, the distance between Lys293α and Lys363α are different in ATP-bound, apo-like and 
Hsp70-bound models. In the case of these models, the ATP-bound Hsp90 serves as a 
representative for Hsp90 in the closed-like state or PU-bound state. The apo-like Hsp90 model 
serves as an un-bound Hsp90 model, and the Hsp70-bound model serves as a representative for 
Hsp90 in the open-like state or GA-bound state. In the Hsp70-bound model, which likely 
resembles the GA-bound conformational states, the shorter distance might have limited the 
location of side-chains for the cross-linking reaction. In summary, the Hsp90 conformational 
states targeted by PU-H71 and GA are similar in gross secondary and tertiary structures. The 
most significant differences center around the nucleotide-binding pocket, the NTD/MD interface, 
and the relative location between MD and CTD. Cumulatively, our data suggest that PU-H71 
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EFFECTS OF PHOSPHOMIMETIC MUTATIONS AND PHOSPHORYLATION-NULL 
MUTATIONS ON HSP90 
 
I. Hsp90 Phosphomimetic Mutations and Phosphorylation-Null Mutations 
 As previously identified in Chapter 2, it was found that PU and GA target distinct Hsp90 
conformational subpopulations, where PU targets Hsp90 in a more phosphorylated state that GA. 
In PU pulldowns of Hsp90, two phosphorylated residues were identified, Ser226ß and Ser 255ß 
(Fig. 6A and 6B), that were not detected in GA pulldowns. Significant decrease of the 
phosphorylated residues in GA pulldowns indicated the importance of the residues in regulating 
Hsp90’s interactions with its co-chaperones in the epichaperome, which is targeted by PU. 
S226/S255Hsp90ß are found in the charged linker between the NTD and MD. This region also 
helps regulate the interactions between Hsp90 and its co-chaperones and client proteins6. The 
enrichment of phosphorylation in PU-bound Hsp90 implicates the possible role of S226 and 
S255 in stabilizing Hsp90 in a conformation favorable for co-chaperone and client protein 
binding. One co-chaperone of interest to us was Aha1, which was found to be in higher 
abundance in PU pull-downs (PDs) than the GA PDs (Table 3). Aha1 has also been associated 
with the charged linker region6, further suggesting that both Ser226 and Ser255 could play a role 
in the association between Hsp90 and Aha1.  
 Based on the evidence suggesting phosphorylation at the charged linker region may play 
a role in Hsp90’s conformation in the epichaperome and association with co-chaperones, 
mammalian expression vectors were generated containing Hsp90ß (Fig. 8) with mutations at 
S226 and S255 that either mimic phosphorylation (S226E and S255E) or cannot be 
phosphorylated (S226A/S226P and S255A/S255P). In phosphomimetic plasmids, both S226 and 
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S255 were mutated to glutamate residues, as glutamate is chemically like phosphorylated serine. 
Multiple phosphorylation-null mutant plasmids were generated, with S226 and S255 either being 
mutated to alanine or proline, which are unable to be phosphorylated. Two FLAG-Hsp90 
phosphorylation-null plasmids were generated. One contained S226A and S255A, while the 
other contained S226P and S255P. One phosphorylation-null mutant plasmid was generated for 
mCherry-Hsp90, which contained S226A and S255A.  
FLAG and mCherry were chosen to be linked to Hsp90 for different reasons. The triple-
FLAG tag can be used to purify our mutant plasmids via immunoprecipitation, which can allow 
us to identify co-precipitating proteins with FLAG-Hsp90 to assess whether the mutations at 
S226 and S255 affect co-chaperone and client protein binding to Hsp90. The mCherry 
fluorescent protein allows for visualization of the proteins using confocal microscopy. Co-
transfection of our mCherry-Hsp90 with a green fluorescent protein-tagged Aha1 (Aha1-GFP) 
followed by colocalization analysis can allow us to investigate whether mutations at S226 and 




      
Figure 8: pCAGGS mammalian expression vectors containing Hsp90ß linked to triple FLAG 








II. Materials and Methods 
Mammalian Cell Culture and Reverse Transfections 
 Mouse embryonic stem cells, E14 cell line, were grown in a 37°C incubator with an 
atmosphere containing 5% CO2. E14 cells were maintained with growth media composed of 
Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum, 2 mM L-glutamine, 1X non-
essential amino acids, 1x penicillin/streptomycin, beta-mercaptoethanol, and leukemia inhibitory 
factor. Growth surfaces were coated with 0.2% gelatin.   
 Reverse transfections were performed immediately following passaging of E14 cells. 
Lipofectamine 3000 Reagent (Thermo Fisher Scientific Cat. # L3000001) was used to transfect 
the E14 cells following the manufacturer’s instructions. Briefly, 625 µL of serum-free media was 
mixed with 12.5 µL of Lipofectamine 3000TM in a microfuge tube. In another tube, 625 µL of 
serum-free media was mixed with 12.5 µL P3000TM and 12.5 µg of DNA. The two tubes were 
combined, mixed, and incubated at room temperature for 15 minutes. After incubation, the 
transfection mixture was passaged E14 cells seeded to 3.3 million cells on 10 cm dishes coated 
with 0.2% gelatin. The total culture volume was brought up to 10 mL with serum-media (normal 
growth maintenance media).   
 
Harvesting Cells 
 Cells were grown according to the above descriptions for about 48 hours or until the cells 
reached 70% confluency. Once at the appropriate confluency, cells were washed with phosphate 
buffered saline (PBS) and removed from the dish using 0.05% trypsin-EDTA. Cell maintenance 
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media was added to neutralize the trypsin digestion then the cells were pelleted. Cell pellets were 
resuspended in 1 mL of PBS then pelleted again in a microcentrifuge tube. The PBS was 
aspirated from the tube so only the pellet remained. The pellet was then flash-frozen in liquid 
nitrogen and transferred to a -80°C freezer for long term storage. 
 
Cell Pellet Lysis 
 Harvested E14 cell pellets were taken from storage in -80°C and thawed at room 
temperature. Pellets were resuspended in felts lysis buffer (20mM HEPES pH 7.4, 145 mM KCl, 
5 mM MgCl2, 0.01% NP-40) supplemented with sodium butyrate, dithiothreitol (DTT), 
phenylmethylsulfonyl fluoride (PMSF), nicotinamide, sodium molybdate, pepstatin A, aprotinin, 
leupeptin, bestatin, and PhosStop (Sigma).  After resuspension, the cells were lysed using 
sonication. The lysate was centrifuged at 13,000 RPM twice at 4°C and the protein-containing 
supernatant was transferred to a clean tube. Protein concentration was determined using the 
Invitrogen Qubit 2.0. Protein samples were then prepared using SDS-PAGE sample buffer and 
run through SDS-PAGE for protein separation. 
 
Plasmid Construction 
 FLAG-Hsp90 and mCherry-Hsp90 plasmids were assembled from two plasmids: Hsp90 
HA (Addgene Plasmid #22487) and pCAGGS-mCherry (Addgene Plasmid #41583). The 
mCherry-Hsp90 plasmid was constructed using PCR amplification of Hsp90 within the Hsp90 
HA plasmid using the forward primer 5’-
CGGTCCGGACCGATGCCAGAGGAAGTGCACCATGGAGA-3’, underlined is the BspEI 
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restriction enzyme cut site, and the reverse primer 5’-
GGAAGATCTTCCCTAATCGACTTCTTCCATGCGAGA-3’, underlined is the BglII 
restriction enzyme cut site. The PCR product and pCAGGS-mCherry plasmid were then digested 
with BspEI (NEB Cat. #R0540S) and BglII (NEB Cat. #R0144S) following the manufacturer’s 
protocol. After digestion, the PCR product and pCAGGS-mCherry plasmids were ligated 
together using Quick Ligation Kit (NEB Cat. # M2200S) following the manufacturer’s protocol. 
The FLAG-Hsp90 plasmid was generated by GENEWIZ using similar methods. The Hsp90 
within the Hsp90 HA plasmid was amplified using primers containing a triple FLAG tag 
sequence. The amplification product was then ligated into the pCAGGS plasmid using the 
restriction enzymes XbaI and BspEI. Plasmid sequences were verified by GenScript. Each 
plasmid contained an ampicillin resistance gene to allow for plasmid amplification using 
Escherichia coli.  
 
Plasmid Mutagenesis 
 After the mCherry and FLAG-Hsp90 plasmids were generated, they were sent to 
GenScript for mutagenesis and sequence verification. In the mCherry-Hsp90 plasmid S226 and 
S255 were mutated to alanine for phosphorylation-null plasmids and were mutated to glutamate 
for phosphomimetic plasmids. In the FLAG-Hsp90 plasmids, S226 and S255 were mutated to 
alanine in one plasmid and proline in another plasmid for phosphorylation-null plasmids and 






 First, chemically competent TOP10 E. coli cells were thawed one ice. Once thawed, 50 
μL of TOP10 cells were combined with 5 ng of plasmid DNA in a new 1.5 mL microcentrifuge 
tube. The mixture was incubated on ice for 30 minutes then heat shocked at 42°C for 30 seconds. 
Next, 950 μL of room temperature LB Broth (1% tryptone (wt./vol), 0.5% yeast extract, 
(wt./vol), 1% NaCl (wt./vol)), without antibiotic, was added to the tube. The tube was then 
shaken at 250 RPM for 1 hour at 37°C. While shaking, LB agar plates (1.2% agar (wt./vol), 1% 
tryptone (wt./vol), 0.5% yeast extract (wt./vol), 0.5% NaCl (wt./vol), 100 ug/μL ampicillin) were 
warmed to 37°C. After the incubation, 75 μL of the DNA and TOP10 mixture was spread onto 
the agar plate. The agar plate was incubated at 37°C overnight.   
 
Plasmid Amplification 
 After growing transforming the plasmids into bacteria and growing them on LB plates 
containing ampicillin, one healthy colony was taken from the plate and inoculated into 3 mL of 
LB broth containing ampicillin. This pre-culture was grown for 8 hours then diluted 1:625 in 25 
mL of LB broth containing ampicillin. This culture was grown overnight. The following 
morning, plasmid DNA was extracted from the cells using Qiagen’s CompactPrep Plasmid Midi 
Kit following the manufacturer’s instructions. Following plasmid purification, the plasmid DNA 





Confocal imaging and slide preparation 
 E14 cells were transfected and grown on glass coverslips in a 12-well plate. Prior to 
beginning the cell growth, glass coverslips were exposed to UV light for 30 minutes then only 
the top face, or area where E14 cells would be grown, was coated with 0.2% gelatin for 30 
minutes. The coated slides were then washed with PBS, seeded with E14 cells, and grown to 
70% confluency. Once at 70% confluency, the media was aspirated, and the cells were fixed to 
the glass coverslip with 4% paraformaldehyde in PBS for 20 minutes. Slides were then washed 
twice in PBS for 10 minutes, then permeabilized with 0.1% PBST for 15 minutes while rotating 
at room temperature. Next, the slides were rinsed three times with PBS while rotating at room 
temperature for 10 minutes then incubated in 1 ng/μL of DAPI in PBS for 10 minutes while 
rotating at room temperature away from light. After incubation, the slides were washed twice 
with PBS for 10 minutes. Finally, the slide was placed onto an uncoated microscope slide with 7 
μl of antifade mounting medium (VECTASHIELD) then sealed along the edges with nail polish.     
 Slides were imaged using the Nikon A1R HD confocal inverted microscope. Z-stack 
images were taken to capture fluorescence levels from the top to bottom of E14 cell areas. 
 
mCherry-Hsp90 Immunoprecipitation 
 E14 cells were transfected with the one of the mCherry-Hsp90 plasmids then harvested 
and lysed as previously described. Following cell lysis and determination of protein 
concentration, immunoprecipitation began. mCherry-Hsp90 immunoprecipitation was performed 
using the RFP Selector Resin (NanoTag #N0410). To begin, the RFP Selector Resin was 
resuspended by inverting the tube several times. 20 µL of the now resuspended RFP Selector 
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Resin slurry was transferred to a clean 1.5 mL microcentrifuge tube. Next, the RFP Selector 
Resin was washed with 1 mL of non-supplemented Felts lysis buffer and centrifuged for 1 
minute at 2,000 RCF. After centrifugation, the supernatant was removed, and the wash step was 
repeated for a total of two wash steps. After equilibrating the resin, the lysate was added to the 
beads. The amount of protein added to the beads was normalized based on the lowest lysate 
concentration, so each resin was exposed to the same concentration of protein. The resin and 
beads mixture were incubated for 1 hour at 4°C with head-over-tail-rotation. After incubation, 
the resin was sedimented by centrifugation for 1 minute at 2,000 RCF at 4°C and the non-bound 
fraction or flow-through, was saved in a clean separate tube. After removing the flow-through, 
the beads were washed with 1 mL of non-supplemented Felts lysis buffer and pelleted by 
centrifugation for 1 minute at 2,000 RCF at 4°C. The was step was repeated for two total washes. 
After washing with Felts lysis buffer, wash the beads with 1mL of 1X tris-buffered saline (TBS) 
by centrifugation for 1 minute at 3,000 RCF at 4°C. After washing with TBS, the supernatant 
was completely removed so only the pelleted resin remained. The resin was then resuspended in 
50 µL of 2X SDS-PAGE sample buffer and heated at 95°C for 5 minutes. Next, the resin and 2X 
SDS-PAGE sample buffer was centrifuged for 1 minute at 3,000 RCF at 4°C. The supernatant 
was then transferred to a clean tube then analyzed by running through a 4-18% gradient SDS-
PAGE.   
 
SDS-PAGE and Trypsin digestion 
 After elution from the RFP Selector resin, samples were loaded onto a 4-18% SDS-
PAGE and ran until the tracking dye ran completely off the gel. To visual proteins, the SDS-
PAGE was stained in Coomassie Blue stain (0.1% Coomassie Brilliant Blue R250 (wt./vol), 10% 
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glacial acetic acid (vol/vol), 50% methanol (vol/vol)) then de-stained using a de-stain solution 
(10% glacial acetic acid (vol/vol), 45% methanol (vol/vol), and 45% H2O).   
In-gel digestion was carried out as described previously (Chu et. al 2004)57. Briefly, in-
gel digestion began by excising each entire lane (corresponding to the well that the sample was 
loaded into) of the gel and cutting each lane into eight gel pieces. The eight gel slices per lane 
were diced into gel cubes and were placed in a 0.5mL maximum recovery tube. The small cubes 
were washed with 50 μL of 25 mM NH4HCO3/50% acetonitrile (ACN) and vortexed for 10 
minutes. After each vortex, the supernatant was discarded, and the step was repeated for three 
total washes. Next, the sample was reduced using 100 μL 10 mM DTT (in 25mM NH4HCO3) at 
56°C for 1 hour. After incubation, the supernatant was discarded. Next, the gel pieces were 
alkylated with 100 μL of 55 mM iodoacetamide (in 25mM NH4HCO3) in darkness for 45 
minutes. Again, the supernatant was discarded following incubation. Gel pieces were then 
washed with 25 mM NH4HCO3. Next, the pieces were dehydrated by washing three times with 
25 mM NH4HCO3/50% ACN (vol/vol) then completely dried using a speed-vacuum at room 
temperature. Dried gel pieces were proteolytically digested using various trypsin volumes 
ranging from 15-25μl. The trypsin was prepared by mixing 10 µL of 0.5 mg/mL trypsin 
(Promega Part #V5113) in 90 µL of 25 mM NH4HCO3. The lowest intensity bands received 15 
μl of trypsin in 25 mM NH4HCO3, while the highest intensity bands received 25 μl. Trypsin 
digestion was carried out at 37°C for 4 hours. Following digestion, tryptic peptides were 
extracted twice by vortexing for 20 minutes with 35 μL extraction buffer (50% ACN 
(vol/vol)/2% acetic acid (vol/vol). The extracted peptides were transferred to a clean tube and 
brought down to 3.5 μL using a speed-vacuum. The concentrated sample was brought up to a 




Qualitative and Quantitative Mass Spectrometry Data Analysis 
Briefly, 1μl aliquot of the digestion mixture was injected into a Dionex Ultimate 3000 
RSLCnano UHPLC system (Dionex Corporation, Sunnyvale, CA), and separated by a 75 μm × 
25 cm PepMap RSLC column (100 Å, 2 μm) at a flow rate of ~450 nl/min. The eluant was 
connected directly to a nanoelectrospray ionization source of an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, Waltham, MA). LC-MS data was acquired in an information-
dependent acquisition mode, cycling between a MS scan (m/z 315–2,000) acquired in the 
Orbitrap, followed by low-energy CID analysis on three most intense multiply charged 
precursors acquired in the linear ion trap. 
 
III. Results and Discussion 
Phosphomimetic and phosphorylation-null mutations do not significantly alter association 
between mCherry-Hsp90 and GFP-Aha1 
 To investigate the effect of Hsp90 S226 and S255 phosphorylation on Hsp90 and Aha1 
association, an mCherry-Hsp90 (generated for this thesis) and an Aha1-GFP (Sino Biological 
Cat. #HG11393-ACG) were co-transfected into E14 cells. The mCherry was linked to the NTD 
of Hsp90, while the GFP was linked to the C-terminus of Aha1. Transfection of both the 
plasmids into E14 cells and imaging with confocal microscopy did not reveal conclusive 
differences between mCherry-Hsp90 association with Aha1-GFP when Hsp90 S226 and S255 
were mutated to glutamate as a phosphomimetic and alanine as a phosphorylation-null mutant 
(Fig. 9). In each of the representative images showing a merge between the mCherry and GFP 
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channels, there exist regions where Aha1-GFP is expressed and is not associated with mCherry 
and there also exist regions where mCherry-Hsp90 is expressed and is not associated with Aha1-
GFP. There also exist regions where mCherry-Hsp90 and Aha1-GFP are expressed in the same 
area, potentially suggesting association between mCherry-Hsp90 and Aha1-GFP. Between the 
WT, AA, and EE mutated mCherry-Hsp90, there are no drastic differences showing more or less 
association between mCherry-Hsp90 and Aha1-GFP, which could imply that phosphorylation of 
S226 and S255 may not play a large role in association between Hsp90 and Aha1. However, 
there are many other factors to consider.  
 In this experiment, there was essentially an overexpression of either an unmutated Hsp90 
or mutated Hsp90 through transfection with the plasmids, so endogenous Hsp90 is still present. 
Since endogenous Hsp90 is still expressed within the cells, transfected mCherry-Hsp90 could 
dimerize with endogenous Hsp90. Therefore, Aha1-GFP could be associating with endogenous 
Hsp90 rather than our transfected mutant Hsp90. We placed our tag at the N-terminus of Hsp90 
because in a previous study, the C-terminal TAP-tagged Hsp90 constructs identified 
considerably fewer proteins with lower spectra counts than the N-terminal TAP constructs65. 
Furthermore, 40x magnification using the confocal microscope might not have provided 
sufficient resolution on cellular colocalization. Also, a recent study indicated the importance of 
the C-terminal domain of Aha1 in a dynamic Hsp90/Aha1 association that involves domains of 








Figure 9: Confocal microscopy images of E14 cells transfected with one mCherry-Hsp90 mutant and Aha1-GFP. Cells were also 
stained with DAPI. From top to bottom, the row identifies are as follows: E14 cells transfected with unmutated S226/S255 (WT) 
mCherry-Hsp90, S226A/S255A phosphorylation-null mutant (AA) mCherry-Hsp90, and S226E/S255E phosphomimetic mutant (EE) 
mCherry-Hsp90. From left to right, the column identities are as follows: DAPI stain channel, mCherry channel, GFP channel, and 




N-terminal mCherry fusion protein serves as a better target for Hsp90 immunoprecipitation than 
Triple FLAG 
 Initially, the plan of this project was to develop two plasmids to investigate the effects of 
phosphorylation on Hsp90’s association with co-chaperones and client proteins. The FLAG-
Hsp90 plasmid was to be used for immunoprecipitation of Hsp90 for assessment of co-
precipitating clients and co-chaperones that associated with the mutant Hsp90’s, while the 
mCherry-Hsp90 was to be used for visual assessment of mutant Hsp90’s association with GFP-
Aha1. During the immunoprecipitation experiments, there were issues purifying the triple-
FLAG-tagged Hsp90. For the FLAG immunoprecipitation experiment, mouse monoclonal anti-
FLAG M2 antibody (Sigma Aldrich Cat. #F3165-.2MG) was used. Treatment of lysates with the 
FLAG M2 antibody did not show significant differences between samples transfected with 
FLAG-tagged Hsp90 and samples without FLAG-tagged Hsp90 (Fig. 10). Each sample was 
treated with the antibody, as seen through the heavy and light chains of the antibody being 
visible in each lane around 51 kDa and 24 kDa. The “E14 Non-transfected IP” lane should only 
have the heavy and light antibody chains visible; however, there are still many proteins visible in 
the lane, signifying nonspecific binding with the FLAG antibody. Furthermore, the triple FLAG 
epitope has a molecular weight of about 3 kDa, so if it is linked to Hsp90, the total molecular 
weight is about 93kDa. In each of the transfected lanes (WT, AA, EE, and PP FLAG-Hsp90), 
there is no significant enrichment of a protein near the 93kDa region. There is a band near the 
90kDa region; however, since it is present in the non-transfected lanes as well as the transfected 
lanes, it is likely an endogenous protein, perhaps endogenous Hsp90 nonspecifically binding to 
the antibody. Lack of enrichment of the FLAG-Hsp90 could be due to the small size of the 







Figure 10: SDS-PAGE showing FLAG immunoprecipitation (IP) results of non-transfected E14 
samples and transfected E14 samples. From left to right, the identities of the sample lanes are as 
follows: protein standard, non-transfected E14 cells, unmutated S226/S255 (WT) FLAG-Hsp90, 
S226A/S255A phosphorylation-null mutant (AA) FLAG-Hsp90, S226E/S255E phosphomimetic 
mutant (EE) FLAG-Hsp90, and S226P/S255P phosphorylation-null mutant FLAG-Hsp90. 
 
Hsp90 associates with other co-chaperones and client proteins. The FLAG peptide was linked to 
the NTD of Hsp90, and co-chaperones that associate with Hsp90’s NTD include CDC37, Aha1, 
and p23. Binding of these co-chaperones to the NTD of Hsp90 could prevent the anti-FLAG 
antibody from accessing the FLAG epitope. Furthermore, during Hsp90’s conformational cycle, 
the NTD’s of each monomer associate with each other to allow for ATP hydrolysis2, and this 
association between NTD’s could also potentially prevent the FLAG epitope from being exposed 












 Due to the nonspecific binding and lack of enrichment of FLAG-Hsp90 near the 92kDa 
region, the mCherry-Hsp90 plasmid was used to assess the effects of phosphomimetic and 
phosphorylation-null mutations on Hsp90 co-chaperone and client protein association using E14 
cells transfected with our mCherry-Hsp90 constructed plasmids. Using the RFP Selector 
(NanoTag Cat. #N0410), a high-affinity single-domain antibody (sdAb) covalently immobilized 
on 4% cross-linked agarose, there is no elution of the antibody when boiled in SDS-PAGE 
sample buffer. In the samples treated with the RFP Selector, there are no proteins precipitated in 
the “E14 Non-transfected IP,” showing the RFP Selector is highly specific towards mCherry. 
The “mCherry Positive Control” sample displayed two distinct bands near the 25kDa and 30kDa. 
mCherry is about 26.7kDa (Fig. 11). Since mCherry is about 26.7kDa, if it is linked to Hsp90, 
the size of mCherry-Hsp90 should be about 117kDa. A band near the 117kDa region (red box in 
Fig. 11) is visible in each of the mCherry-Hsp90 samples (Fig. 11), showing that the RFP 
Selector identified the mCherry in the mCherry-Hsp90 samples. Additionally, there is a band 
near the 90kDa region, which is likely endogenous Hsp90 that dimerized with the mCherry-
Hsp90 after it was transfected into the cells.  
In-gel digestion was performed on each mCherry-Hsp90 IP lane (Fig. 11) by dicing the 
lanes into eight sections and performing LC-MS/MS analysis to identify proteins associated with 
phosphomimetic (EE) mutations on Hsp90 and phosphorylation-null (AA) mutations on Hsp90. 
To quantify the protein amount of each identified protein, spectra counting of identified peptides 
was used. The top proteins identified in each sample were the mCherry-Hsp90 protein, 
endogenous Hsp90α, and Trap1, a mitochondrial analogue to Hsp90 (Table 5). The co-
precipitating proteins were most abundant based on peptide count in the WT mCherry-Hsp90. 









Figure 11: SDS-PAGE showing mCherry immunoprecipitation (IP) results of non-transfected 
E14 samples and transfected E14 samples. From left to right, the identities of the sample lanes 
are as follows: protein standard, non-transfected E14 cells, mCherry positive control (pCAGGS-
mCherry plasmid), unmutated S226/S255 (WT) FLAG-Hsp90, S226A/S255A phosphorylation-
null mutant (AA) FLAG-Hsp90, S226E/S255E phosphomimetic mutant (EE) FLAG-Hsp90, and 
another protein standard. The bands enclosed by the red box are the mCherry-Hsp90 mutants 
purified by IP. 
 
were less abundant. AA mCherry-Hsp90 had the fewest co-precipitating proteins present. The 
lack of several known Hsp90 co-chaperones in the null-phosphorylation (AA) mutant samples 
and a higher abundance of co-chaperones in the phosphomimetic (EE) mutant samples, strongly 
suggests that phosphorylation at S226 and S255 are important for co-chaperone and client 
protein binding to Hsp90. However, many known clients are missing from the co-precipitation 













Esrrb, Brat1, PurA, and Oct4. This IP data was only obtained from a single experiment, so the 
experiment needs to be replicated to assess the statistical significance of the results. IP conditions 
should be optimized to precipitate more proteins. However, there is also the possibility that the 
bigger mCherry tag might provide steric hindrance for client protein binding during IP 
conditions. An additional factor to consider with the co-precipitating proteins from the mCherry-
Hsp90 IP is that endogenous Hsp90 was also purified. This indicates that a subpopulation of 
mCherry-Hsp90 is likely dimerizing with endogenous Hsp90. Co-chaperones and client proteins 
could then be associating with endogenous Hsp90 in the dimer, so precipitation and quantitation 
of these proteins is not a true indicator of the effect a S226A/S255A or S226E/S255E mutation 
has on co-chaperone and client protein interaction with Hsp90. However, preliminary data shows 
that S226 and S255 phosphorylation on Hsp90 play an important role in regulating co-chaperone 
















Table 5: Proteins identified by MS following in-gel digestion of mCherry-Hsp90 IP SDS-PAGE 
samples 
Proteins 
Peptide count in 
WT mCherry-Hsp90 
IP  
Peptide count in 
 AA mCherry-
Hsp90 IP 
Peptide count in 
EE mCherry-
Hsp90 IP 
mCherry-Hsp90ß 1392 880 1323 
Hsp90α 540 298 465 
Hsp90ß 0 0 0 
Trap1 59 32 55 
Co-chaperones:    
Hsc70 151 72 133 
Bip 29 7 19 
Stil/Hop 90 54 77 
FKBP4 6 0 0 
FKBP5 9 0 2 
Tpr1 11 0 9 
Aha1 4 0 9 
Cdc37 13 0 11 
Tom34 18 0 8 
Tom40 0 0 3 
Tom70 1 0 5 
Sgt1 8 0 11 
Stub1/CHIP 18 0 7 
Substrates:    
Cdk1 3 2 4 
Cdk4 8 1 4 
Cdk9 5 1 6 













CONCLUSION AND FUTURE DIRECTIONS 
The main aims of this project were to characterize Hsp90 modifications targeted by GA 
and PU then generate posttranslationally modified Hsp90 mutants and assess the effects of PTMs 
on Hsp90 co-chaperone and client proteins. In terms of the first goal, the results indicated three 
main findings: PU and GA target distinct Hsp90 subpopulations, PU and GA target distinct 
posttranslational modification states in Hsp90, and PU and GA target distinct conformational 
states in Hsp90. Treatment of Hsp90 lysates with PU and GA followed by in-gel digestion and 
LC-MS/MS analysis revealed PU mostly targets the complexed or epichaperome subpopulation 
of Hsp90, while GA mainly targets uncomplexed Hsp90. This experimental data also indicated 
that PU targets Hsp90 in a more phosphorylated state than GA, suggesting PU and GA target 
distinct posttranslational modification states. Finally, chemical crosslinking of the PU and GA 
treated lysates revealed different conformational states of Hsp90 targeted by PU and GA, as PU 
targeted Hsp90 in a closed-like conformation, while GA targeted Hsp90 in an open-like 
conformation. 
In terms of the second goal, posttranslationally modified Hsp90 mutants were generated 
by constructing two mammalian expression plasmids containing Hsp90 with two mutated serine 
residues, which were found to be phosphorylated and enriched in PU PD Hsp90 samples. 
Phosphomimetic Hsp90 mutants were generated by mutating both serine residues to glutamate. 
Phosphorylation-null Hsp90 mutants were generated by mutating both serine residues to alanine 
or proline. Overall, two sets of mammalian expression vectors were generated: one contained a 
triple FLAG epitope linked to Hsp90, and the other contained an mCherry fusion protein linked 




experiments and mCherry-Hsp90 for microscopy experiments; however, the triple FLAG-Hsp90 
proved difficult to immunoprecipitate, so mCherry-Hsp90 was used for both microscopy and 
immunoprecipitation experiments. Co-transfection of E14 cells with mCherry-Hsp90 and Aha1-
GFP, displayed no clear differences between Aha1 association with Hsp90 phosphomimetic and 
phosphorylation-null mutants, suggesting that S226 and S255 are not critical for Hsp90-Aha1 
association. Despite no clear visual differences in fluorescent microscopy data, preliminary 
immunoprecipitation results suggest that phosphomimetic and phosphorylation-null mutations do 
alter co-chaperone and client protein association with Hsp90. Phosphorylation-null mutations at 
S226 and S255 of Hsp90 caused fewer co-chaperones and client proteins to associate with 
Hsp90. Unmutated Hsp90 and phosphomimetic mutations at S226 and S255 had similar levels of 
associated co-chaperones and client proteins, suggesting that phosphorylation may regulate 
protein binding to Hsp90. Further investigation and replicated experiments of the 
immunoprecipitation of mCherry-Hsp90 is necessary to conclude whether these mutations are 
significantly impacting co-chaperone and client protein association with Hsp90. 
Moving forward, there are many directions this project could lead. Our results indicated 
that in Hsp90 subpopulations targeted by PU-H71 existed in a more phosphorylated state than 
GA targeted Hsp90. Future projects could investigate if other posttranslational modifications on 
Hsp90 alter its binding to PU and GA to assess if the epichaperome is affected by different 
modifications. Additionally, the plasmids transfected into E14 cells allowed for overexpression 
of an Hsp90 mutant protein, but endogenous Hsp90 was still present in the cell. Future projects 
could potentially investigate generating an inducible Hsp90 knockdown to remove endogenous 
Hsp90. Then create a stable transfection in which cells transfected with Hsp90 mutant plasmids 




true assessment of Hsp90 mutations without interaction with endogenous Hsp90, since the 
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